SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Isis Pharmaceuticals, Inc. Announces Expedited Development of ISIS-TTR Rx and Amendment to the Collaboration With GlaxoSmithKline to Support Phase 2/3 Study